肿瘤靶向药物大盘点

2.此价格为北京协和医保后价格，其他医院价格可能略有不同。

非小细胞肺癌靶向药物

表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）：

在亚洲EGFR整体突变率为30%-50%，年轻、不吸烟和女性腺癌患者EGFR突变频率甚至达到56%-70%，使用靶向治疗机会更多。但没有EGFR 敏感突变的患者中EGFR-TKI疗效低于化疗，所以，治疗时关键要明确适合此肿瘤，不花冤枉钱，不耽误病情。

靶向药对比

▼

<< 滑动查看更多 >>

图片来源：自己做的

间变性淋巴瘤激酶 ( ALK)基因重排和ROS1基因重排

ALK突变发生率约5.05%，多出现年轻、男性不吸烟的非小细胞肺癌患者，其与 EGFＲ突变基因不同时存在。

ROS1基因突变率较低，仅为1-2%。

靶向药对比

▼

<< 滑动查看更多 >>

图片来源：自己做的

BRAF基因突变：

发生率约2%-4%，即在100个人中只有2-4个人存在BRAF基因突变。

RET基因重排:

发生率1%-2%，即在100个人中只有1-2个人存在RET基因重排。

NTRK基因融合

发生率0-2%，即在100个人中只有0-2个人存在NTRK基因融合。

“当你老了，头发白了，睡意昏沉......”唱出多少人生感慨，当您病了，身心累了，度日如年......谱写无数患者心声，笔者有心，读者神会，瞄准靶心，直击靶点，愿康者更加健壮，愿患者康复在望！

参考文献

1. FUJIWARA K,KIURA K,UEOKA H,et al.Drmaticeffect of ZD1839 (‘Iressa’)in a patient with advanced non-small-cell lung cancer and poor performance status[J].LungCancer,2003,40(1):73-76.

2.ROSELL R,CARCERENY E,GERVAIS R,et al.Erlotinibversus standard chemotherapy as first-line treatment for Eu-ropean patients with advanced EGFR mutation-positve non-small-cell lung cancer (eurtac):Amulticentre,open-label,randomised phase 3trial[J].Lancet Oncol,2012,13(3):239-246.

3. KOBAYASHI S,BOGGON T J,DAYARAM T,et al.EGFRmutation and resistance of non-sml-cell lung cancer to ge-fitinib[J].N Enl J Med,2005,352(8):786-792.

4. SEQUIST L V,YANG J C,YAMAMOTO N,et al.PhaseⅢstudy of afatinib or cisplatin plus pemetrexed in patients withmetastatic lung adenocarcinoma with EGFR mutations[J].JClin Oncol,2013,31(27):3327-3334.

5. WU Y L,CHENG Y,ZHOU X D,et al.Dacomitinib versusgefitinib as first-line treatment for patients with EGFR-muta-tion-positive non-small-cell lung cancer(archer 1050):A ran-domised,open-label,phase 3trial[J].Lancet Oncol,2017,18(11):1454-1466.

6. SORIA J C,OHE Y,VANSTEENKISTE J,et al.Osimer-tinib in untreated EGFR- mutated advanced non-small-celllung cancer[J].N Engl J Med,2018,378(2):113-125.

7. RAMALINGAM S S,YANG J C H,LEE C K,et al.Osimer-tinib as first-line treatment of EGFR mutation-positive ad-vanced non-small-cell lung cancer[J].JCO,2018,36(9):841-849.

8. WU Y L,LU S,LU Y,et al.Results of profile 1 029,aphaseⅢ comparison of first-line crizotinib versus chemothera-py in east Asian patients with ALK-positive advanced non-small cell lung cancer[J].J Thorac Oncol,2018,13(10):1539-1548.

9. SORIA J C,TAN D S W,CHIARI R,et al.First-line ce-ritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4):Aran-domised,open-label,phase 3study[J].Lancet,2017,389(10072):917-929.

10. PETERS S,CAMIDGE D R,SHAW A T,et al.Alectinibversus crizotinib in untreated ALK-positive non-small-celllung cancer[J].N Engl J Med,2017,377(9):829-838.

11. RIKOVA K,GUO A,ZENG Q,et al.Global survey of phos-photyrosine signaling identifies oncogenic kinases in lungcan-cer[J].Cell,2007,131(6):1190-1203.

12. CUI J J,ZHAI D Y,DENG W,et al.P3.02a-009 TPX-0005:A multi-faceted approach to overcoming clinical resist-ances from current ALK or ROS1inhibitor treatment in lungcancer topic:ALK biomarkers[J].J Thorac Oncol,2017,12(1):S1164-S1165.

13. PLANCHARD D,SMIT E F,GROEN H J M,et al.Dab-rafenib plus trametinib in patients with previously untreatedBRAFV600E-mutant metastatic non-small-cell lung cancer:Anopen-label,phase 2trial[J].Lancet Oncol,2017,18(10):1307-1316.

14. GAUTSCHI O,MILIA J,FILLERON T,et al.TargetingRET in patients with RET-rearranged lung cancers:Resultsfrom the global,multicenter RET registry[J].J Clin Oncol,35(13):1403-1410.

15. SUBBIAH V,GAINOR J F,RAHAL R,et al.Precision tar-geted therapy with BLU-667for RET-driven cancers[J].Can-cer Discov,2018,8(7):836-849.

▲上下滑动查看更多

东单九号院

面向大众普及的医学资讯

来自东单三条九号的校友

图片来源：正版图库

1.建议您去办特病症，之后方可享用医保价。

2.此价格为北京协和医保后价格，其他医院价格可能略有不同。